down arrow

Standard BioTools, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US34385P1084
USD
0.97
-0.01 (-1.01%)

Mar 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Cerus Corp.
NeuroPace, Inc.
Sanara MedTech, Inc.
ZimVie, Inc.
Anika Therapeutics, Inc.
AVITA Medical, Inc.
Standard BioTools, Inc.
Allurion Technologies, Inc.
Accuray, Inc.
Pulse Biosciences, Inc.
Alpha Tau Medical Ltd.

Why is Standard BioTools, Inc. ?

1
Poor long term growth as Operating profit has grown by an annual rate -187.08% of over the last 5 years
2
Negative results in Sep 25
  • INTEREST(9M) At USD 0.02 MM has Grown at inf%
  • DEBT-EQUITY RATIO (HY) Highest at -41.91 %
  • OPERATING PROFIT MARGIN(Q) Lowest at -111.86 %
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -15.12%, its profits have fallen by -14.3%
4
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -15.12% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Standard BioTools, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Standard BioTools, Inc.
-16.05%
-0.88
67.13%
S&P 500
14.9%
0.77
19.29%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
0.45%
EBIT Growth (5y)
-187.08%
EBIT to Interest (avg)
-41.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.55
Sales to Capital Employed (avg)
0.34
Tax Ratio
0.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
84.50%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.92
EV to EBIT
-1.66
EV to EBITDA
-1.86
EV to Capital Employed
0.85
EV to Sales
1.38
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-51.00%
ROE (Latest)
-23.08%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -37.89 MM

-22What is not working for the Company
INTEREST(9M)

At USD 0.02 MM has Grown at inf%

DEBT-EQUITY RATIO (HY)

Highest at -41.91 %

OPERATING PROFIT MARGIN(Q)

Lowest at -111.86 %

RAW MATERIAL COST(Y)

Grown by 11.86% (YoY

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.02 times

NET SALES(Q)

Lowest at USD 19.55 MM

Here's what is working for Standard BioTools, Inc.

Net Profit
Higher at USD -37.89 MM
than preceding 12 month period ended Sep 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Here's what is not working for Standard BioTools, Inc.

Interest
At USD 0.02 MM has Grown at inf%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Sales
At USD 19.55 MM has Fallen at -56.52%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Operating Profit Margin
Lowest at -111.86 % and Fallen
In each period in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Debt-Equity Ratio
Highest at -41.91 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Net Sales
Lowest at USD 19.55 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (USD MM)

Inventory Turnover Ratio
Lowest at 2.02 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost
Grown by 11.86% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."